 Open double-blind long-term study vigabatrin chronic epilepsy open double-blind long-term study vigabatrin gamma-vinyl-GABA GVG patients treatment-resistant epilepsy standard antiepileptic drugs AEDs novel design parallel double-blind placebo-controlled phase number patients placebo determination optimum dose GVG patient initiation double-blind phase study phases first phase period baseline observation second phase GVG previous AEDs weeks first weeks phase dose GVG absence adverse effects constant next weeks end open phase seizure frequency weeks constant treatment baseline seizure frequency patient Patients reduction frequency seizure type open phase responders responders third double-blind phase wither active GVG treatment placebo weeks Thirty-three patients study patients initial open phase patients reduction equal frequency seizure types eligible double-blind phase GVG